# Mitochon Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mitochon-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Blue Bell, US
- Website: www.mitochonpharma.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Nov 5, 2014)
- Investors on record: 1

## About

Mitochon Pharmaceuticals specializes in developing innovative therapeutics targeting mitochondrial dysfunction to tackle serious neurodegenerative and neuromuscular diseases. Their unique approach aims to enhance cellular function and energy expenditure in affected patients.Founded in 2014, Mitochon Pharmaceuticals, Inc. is based in Blue Bell, US. The company focuses on therapies for mitochondrial dysfunction affecting neurodegenerative conditions. Co-founded by John Geisler and Robert Alonso, the company has successfully raised a total of USD 1.60 mn through various funding rounds, with the latest funding round led by Ben Franklin Technology Partners on June 23, 2020.Mitochon Pharmaceuticals specializes in developing therapeutics aimed at mitochondrial dysfunction, specifically for conditions like Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD), and Alzheimer’s Disease (AD). Their products utilize a platform based on chemical uncouplers or ionophores to enhance energy expenditure and promote cellular survival, addressing issues like calcium overload and oxidative stress. The company primarily serves healthcare providers and patients in North America and Europe, focusing on significant unmet medical needs in these regions.Mitochon Pharmaceuticals generates revenue through strategic partnerships and collaborations with healthcare providers and research institutions. These engagements typically involve licensing agreements aimed at developing and commercializing their mitochondrial-targeting therapies. While specific pricing plans have not been disclosed, revenue is likely structured around milestone payments achieved during clinical trials or product launches, reflecting their commitment to tailor solutions for critical therapeutic gaps in patient care.Mitochon Pharmaceuticals plans to leverage recent funding to expand its therapeutic offerings and access new markets. They are currently developing additional products aimed at neurodegenerative diseases, with specific release dates to be announced. The company is also targeting expansion into broader European markets to reach more healthcare providers and patients. The funding received in June 2020 from the National Institutes of Health will support these initiatives, enhancing their research and development capabilities.

## Funding rounds

- Seed, Nov 5, 2014, $0.3M — Ben Franklin Technology Partners

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed